Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer
The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Abstract
Bone is the primary anatomical site of breast cancer metastasis, and bone metastasis is associated with increased morbidity and mortality. Mesenchy‐mal stem cells (MSC) are a predominant fibroblast cell population within the bone marrow, and metastatic breast cancer cells that seed within bone would predictably encounter MSC or their soluble factors. Therefore, we examined the impact of primary human MSC on a panel of estrogen receptor‐alpha (ERα)‐positive (MCF‐7, T47D, BT474, and ZR‐75–1) and ERα‐negative (MDA‐MB‐231 and MDA‐MB‐468) human breast tumor cell lines. All ERα‐positive breast tumor cell lines displayed low basal activation of signal transducer and activator of transcription 3 (STAT3) until exposed to MSC, which induced chronic phosphorylation of STAT3 on tyrosine‐705. Paracrine IL‐6 was found to be the principal mediator of STAT3 phosphorylation in coculture studies, and MSC induction of STAT3 phos‐phorylation was lost when IL‐6 was depleted from MSC conditioned media or the IL‐6 receptor was blocked on tumor cells. Enhanced tumor cell growth rates were observed in the ERα‐positive mammary tumor cell line MCF‐7 after paracrine and autocrine IL‐6 exposure, where MCF‐7 growth rates were enhanced by > 2‐fold when cocultured with MSC in vitro and even more pronounced in vivo with autocrine IL‐6 production.—Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., Hall, B. M. Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer. FASEB J. 21, 3763–3770 (2007)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“IL-6 is an MSC-secreted inflammatory cytokine displaying pro-survival, pro-growth and pro-angiogenic activities [11], which has been implicated in tumor progression of various cancers including breast cancer [113, 114].”
From Mesenchymal stem cell secretome and regenerative therapy after cancer (2013) · cites this paper as [113]
In the citing paper
“The production of trophic factors from MSCs including VEGF, chemokine CCL5 and IL6 (activation STAT-3) has been connected with tumour growth and metastasis in Burkitt's lymphoma, breast cancer, colonic cancer and chronic myeloid leukaemia [69], [70], [71], [72], [73].”
From Mesenchymal stromal cells for bone sarcoma treatment: Roadmap to clinical practice (2019) · cites this paper as [70]
Citations
Cites
Multilineage potential of adult human mesenchymal stem cells
Pittenger, M. F., Mackay, A. M., Beck, S. C., Jaiswal, R. K., Douglas, R., Mosca, J. D., Moorman, M. A., Simonetti, D. W., Craig, S., & Marshak, D. R. (1999) · Science · doi:10.1126/science.284.5411.143 · Cited by 21,052 · cited 1×
“Mesenchymal stem cells (MSC), also referred to as bone marrow stromal cells, are a common fibroblastic cell population within bone that regulates hematopoiesis, has a robust ability to self-renew, can differentiate into multiple mesenchymal cell lineages, and constitutively produces IL-6 ( 14 , 15).”
BackgroundCaplan, A. I. (1991) · Journal of Orthopaedic Research · doi:10.1002/jor.1100090504 · Cited by 6,548
Kalluri, R., & Zeisberg, M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1877 · Cited by 4,538 · cited 1×
“A growing body of evidence demonstrates that stromal cell fibroblasts are influential players in tumor progression and metastasis ( 9 ).”
BackgroundOrimo, A., Gupta, P. B., Sgroi, D. C., Arenzana-Seisdedos, F., Delaunay, T., Naeem, R., Carey, V. J., Richardson, A. L., & Weinberg, R. A. (2005) · Cell · doi:10.1016/j.cell.2005.02.034 · Cited by 3,759
Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway
HEINRICH, P. C., BEHRMANN, I., MÜLLER-NEWEN, G., SCHAPER, F., & GRAEVE, L. (1998) · Biochemical Journal · doi:10.1042/bj3340297 · Cited by 2,130 · cited 3×
“Signal transducer and activator of transcription 3 (STAT3) is one of the primary intracellular targets activated after exposure to IL-6 (18), and STAT3 activation has been connected with enhanced tumor cell growth, survival, and immune evasion in breast cancer (22–24).”
BackgroundInfluentialCrosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment
Yu, H., Kortylewski, M., & Pardoll, D. (2007) · Nature Reviews Immunology · doi:10.1038/nri1995 · Cited by 1,804
Autocrine generation and requirement of BSF-2/IL-6 for human multiple myelomas
Kawano, M., Hirano, T., Matsuda, T., Taga, T., Horii, Y., Iwato, K., Asaoku, H., Tang, B., Tanabe, O., Tanaka, H., et al. (1988) · Nature · doi:10.1038/332083a0 · Cited by 1,633 · cited 1×
“cancers including multiple myeloma (19), prostate”
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability
Radisky, D. C., Levy, D. D., Littlepage, L. E., Liu, H., Nelson, C. M., Fata, J. E., Leake, D., Godden, E. L., Albertson, D. G., Angela Nieto, M., et al. (2005) · Nature · doi:10.1038/nature03688 · Cited by 1,284
Peister, A., Mellad, J. A., Larson, B. L., Hall, B. M., Gibson, L. F., & Prockop, D. J. (2004) · Blood · doi:10.1182/blood-2003-09-3070 · Cited by 994 · cited 1×
“, C57BL/6, and FVB/N) as described (26) and maintained in RPMI 1640 complete media.”
BackgroundSelf-citationThe role of IL-6 and STAT3 in inflammation and cancer
Hodge, D. R., Hurt, E. M., & Farrar, W. L. (2005) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.016 · Cited by 950 · cited 1×
“Of interest, the bone marrow microenvironment in postmenopausal women maintains stable levels of IL-6 protein, regardless of systemic estradiol levels (33); therefore, it is possible that the bone marrow microenvironment may represent a more favorable tissue for IL-6-responsive ER -positive tumor cells (32, 34).”
Background
Cited by
Iliopoulos, D., Hirsch, H. A., & Struhl, K. (2009) · Cell · doi:10.1016/j.cell.2009.10.014 · Cited by 1,374
“For example, interleukin-6 (IL6) is upregulated in epithelial cancers such as breast and prostate (Sasser et al., 2007; Wegiel et al., 2008).”
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335
“For example, although IL-6 secretion occurs in ER breast cancer cells, no IL-6 expression is detected in various ER+ breast cancer cell lines (Sasser et al., 2007) or in A375 melanoma.”
BackgroundSpaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Self-citationInterleukin-6 induces an epithelial-mesenchymal transition phenotype in human breast cancer cells
Sullivan, N. J., Sasser, A. K., Axel, A. E., Vesuna, F., Raman, V, Ramirez, N., Oberyszyn, T. M., & Hall, B. M. (2009) · Oncogene · doi:10.1038/onc.2009.180 · Cited by 757
“IL-6 is a pleiotropic cytokine that participates in acute inflammation as the major inducer of C-reactive protein, plays a central role in hematopoiesis (Kishimoto, 2006), and enhances proliferation of breast cancer cells (Sasser et al., 2007b).”
BackgroundMethodResultInfluentialSelf-citationConstitutive activation of STAT 3 in breast cancer cells: A review
Banerjee, K., & Resat, H. (2016) · International Journal of Cancer · doi:10.1002/ijc.29923 · Cited by 611
Metadata
- Authors
- Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M.
- Affiliations
- The Ohio State University (US)
- Center for Childhood Cancer Children's Research Institute Columbus Ohio USA
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2007-06-22
- Volume
- 21
- Issue
- 13
- Pages
- 3763-3770
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1973576115
- Cited by
- 222
- References
- 40
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 14 · 2023: 10 · 2022: 8 · 2021: 9 · 2020: 9 · 2019: 14 · 2018: 13 · 2017: 15 · 2016: 13 · 2015: 14 · 2014: 14 · 2013: 9 · 2012: 17
- FWCI
- 6.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The FASEB Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Elsa U. Pardee Foundation
- Topics
- Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Mesenchymal stem cell research
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Keywords
- interleukin-6, estrogen receptor alpha, breast cancer, mesenchymal stem cells, STAT3 phosphorylation, bone metastasis, paracrine signaling, autocrine signaling, tumor growth, MCF-7 cells, IL-6 receptor
- MeSH terms
- Breast Neoplasms, Humans, Interleukin-6, Cell Line, Tumor, Estrogen Receptor alpha
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer. https://app.cochat.ai/papers/10.1096/fj.07-8832com
- The paper
- Sasser, A. K., Sullivan, N. J., Studebaker, A. W., Hendey, L. F., Axel, A. E., & Hall, B. M. (2007). Interleukin‐6 is a potent growth factor for ER‐α‐positive human breast cancer. The FASEB Journal. https://doi.org/10.1096/fj.07-8832com
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.